Compare KITT & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KITT | CMMB |
|---|---|---|
| Founded | 2014 | 2004 |
| Country | United States | Israel |
| Employees | 51 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.8M | 11.2M |
| IPO Year | N/A | 2023 |
| Metric | KITT | CMMB |
|---|---|---|
| Price | $1.53 | $1.74 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | ★ 347.1K | 45.0K |
| Earning Date | 04-16-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 101.67 |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $45.00 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.39 | $0.87 |
| 52 Week High | $6.93 | $3.86 |
| Indicator | KITT | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 41.30 | 46.66 |
| Support Level | $0.75 | $1.48 |
| Resistance Level | $1.70 | $1.89 |
| Average True Range (ATR) | 0.18 | 0.17 |
| MACD | -0.05 | -0.02 |
| Stochastic Oscillator | 3.47 | 27.06 |
Nauticus Robotics Inc is a technology-driven company specializing in the development of fully electric autonomous robotic solutions for subsea applications. Its portfolio includes autonomous underwater vehicles (AUVs), electric robotic manipulators, a platform-agnostic robotic operating system, and related engineering, consulting and prototype services. The Company's solutions enable autonomous operations for both commercial and defense sectors, with alignment to offshore energy and national security interests. Its addressable markets include upstream, midstream and downstream oil and gas, defense, offshore renewables, seafloor telecommunications, aquaculture, port security, oceanographic research and subsea mining, with current focus on oil and gas operations and defense applications.
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.